Clinicopathological features of patients with de novo CCUS vs t-CCUS
| Variables (median or n; range or %) . | All patients (n = 151) . | CCUS (n = 105) . | t-CCUS (n = 46) . | P value . |
|---|---|---|---|---|
| Age (y), median (range) | 68 (20-99) | 68 (20-99) | 67 (24-83) | .268 |
| Sex (male), n (%) | 91 (60.3) | 67 (63.8) | 24 (52.2) | .208 |
| Active or previous tobacco use, n (%) | 63 (42.6) | 43 (41.8) | 20 (44.4) | .857 |
| Hemoglobin (g/dL), median (range) | 10.9 (6.7-15.9) | 10.6 (6.9-15.9) | 11.4 (6.7-14.8) | .831 |
| MCV (fL), median (range) | 99.2 (80.4-126.7) | 98.4 (80.4-123.2) | 101.4 (86-126.7) | .311 |
| WBC × 109/L, median (range) | 3.5 (0.8-32) | 3.5 (1-32) | 3.5 (0.8-13.4) | .689 |
| ANC × 109/L, median (range) | 1.6 (0.04-19.9) | 1.6 (0.04-19.9) | 1.7 (0.12-9.2) | .854 |
| AMC × 109/L, median (range) | 0.4 (0.01-6.2) | 0.4 (0.01-6.2) | 0.4 (0.03-3.6) | .681 |
| Platelets × 109/L, median(range) | 114 (15-595) | 119 (15-595) | 105 (26-222) | .101 |
| RDW-CV (%), median (range) | 15 (11.7-26.7) | 15 (11.7-26.7) | 15 (12-24.4) | .923 |
| Bone marrow cellularity, n (%) | ||||
| Hypercellular | 55 (36.4) | 47 (44.8) | 8 (17.4) | .002 |
| Hypercellular with atypia | 29 (19.2) | 21 (20) | 8 (17.4) | .824 |
| Hypocellular | 14 (9.3) | 5 (4.8) | 9 (19.6) | .011 |
| Normocellular | 50 (33.1) | 30 (28.6) | 20 (43.5) | .089 |
| Unknown | 3 (1.9) | 2 (1.9) | 1 (2.2) | - |
| Bone marrow blasts (%), median (range) | 0 (0-5)∗ | 0 (0-4) | 1 (0-5) | .026 |
| Abnormal cytogenetics, n (%) | 37 (24.5) | 26 (24.8) | 11 (23.9) | .375 |
| Presence of ringed sideroblasts, n (%) | 26 (13.3) | 15 (14.3) | 5 (10.9) | .926 |
| Number of mutations, median (range) | 2 (0-5) | 2 (0-4) | 1 (0-5) | .551 |
| VAF (%), median (range) | 39 (5-92) | 39 (5-82) | 38.5 (6-92) | .858 |
| Management of disease, n (%) | ||||
| Surveillance only | 112 (74.2) | 75 (71.4) | 37 (80.4) | |
| Hypomethylating agent | 6 (4) | 4 (3.8) | 2 (4.4) | |
| Supportive care (G-CSF, ESA, TPO, and transfusions) | 23 (15.2) | 17 (16.2) | 6 (13) | |
| Immunosuppressive agent | 6 (4) | 6 (5.7) | 0 (0) | |
| Bone marrow transplantation | 0 (0) | 0 (0) | 0 (0) | .544 |
| Vitamin C clinical trial | 4 (2.7) | 3 (2.9) | 1 (2.2) | |
| Progression to MN, n (%) | 28 (17.9) | 16 (15.2) | 12 (26.1) | .171 |
| CMML | 6 (4) | 4 (3.8) | 2 (4.3) | |
| MDS | 15 (9.9) | 8 (7.6) | 7 (15.2) | |
| AML | 6 (4) | 3 (2.9) | 3 (6.5) | |
| BPDCN | 1 (0.6) | 1 (1) | 0 (0) | .491 |
| Follow-up (y), median (range) | 2.2 (0.05-12.6) | 2.5 (0.05-12.6) | 1.5 (0.1-5.9) | .002 |
| Total deaths, n (%) | 44 (29.1) | 26 (24.8) | 18 (39.1) | |
| Malignancy related | 14 (31.8) | 6 (23.1) | 8 (44.4) | |
| Cardiac related | 8 (18.2) | 4 (15.4) | 4 (22.2) | .299 |
| Infection related | 10 (22.7) | 8 (30.1) | 2 (11.1) | |
| Other/multifactorial | 12 (27.3) | 8 (30.1) | 4 (22.2) | |
| CHRS score, median (range) | 12 (8.5-15.5) | 12 (8.5-15.5) | 12 (8.5-15.5) | .574 |
| CHRS risk group, n (%) | ||||
| Low | 16 (10.6) | 9 (8.6) | 7 (15.2) | |
| Intermediate | 70 (46.4) | 50 (47.6) | 20 (43.5) | |
| High | 65 (43.1) | 46 (43.8) | 19 (41.3) | .478 |
| Variables (median or n; range or %) . | All patients (n = 151) . | CCUS (n = 105) . | t-CCUS (n = 46) . | P value . |
|---|---|---|---|---|
| Age (y), median (range) | 68 (20-99) | 68 (20-99) | 67 (24-83) | .268 |
| Sex (male), n (%) | 91 (60.3) | 67 (63.8) | 24 (52.2) | .208 |
| Active or previous tobacco use, n (%) | 63 (42.6) | 43 (41.8) | 20 (44.4) | .857 |
| Hemoglobin (g/dL), median (range) | 10.9 (6.7-15.9) | 10.6 (6.9-15.9) | 11.4 (6.7-14.8) | .831 |
| MCV (fL), median (range) | 99.2 (80.4-126.7) | 98.4 (80.4-123.2) | 101.4 (86-126.7) | .311 |
| WBC × 109/L, median (range) | 3.5 (0.8-32) | 3.5 (1-32) | 3.5 (0.8-13.4) | .689 |
| ANC × 109/L, median (range) | 1.6 (0.04-19.9) | 1.6 (0.04-19.9) | 1.7 (0.12-9.2) | .854 |
| AMC × 109/L, median (range) | 0.4 (0.01-6.2) | 0.4 (0.01-6.2) | 0.4 (0.03-3.6) | .681 |
| Platelets × 109/L, median(range) | 114 (15-595) | 119 (15-595) | 105 (26-222) | .101 |
| RDW-CV (%), median (range) | 15 (11.7-26.7) | 15 (11.7-26.7) | 15 (12-24.4) | .923 |
| Bone marrow cellularity, n (%) | ||||
| Hypercellular | 55 (36.4) | 47 (44.8) | 8 (17.4) | .002 |
| Hypercellular with atypia | 29 (19.2) | 21 (20) | 8 (17.4) | .824 |
| Hypocellular | 14 (9.3) | 5 (4.8) | 9 (19.6) | .011 |
| Normocellular | 50 (33.1) | 30 (28.6) | 20 (43.5) | .089 |
| Unknown | 3 (1.9) | 2 (1.9) | 1 (2.2) | - |
| Bone marrow blasts (%), median (range) | 0 (0-5)∗ | 0 (0-4) | 1 (0-5) | .026 |
| Abnormal cytogenetics, n (%) | 37 (24.5) | 26 (24.8) | 11 (23.9) | .375 |
| Presence of ringed sideroblasts, n (%) | 26 (13.3) | 15 (14.3) | 5 (10.9) | .926 |
| Number of mutations, median (range) | 2 (0-5) | 2 (0-4) | 1 (0-5) | .551 |
| VAF (%), median (range) | 39 (5-92) | 39 (5-82) | 38.5 (6-92) | .858 |
| Management of disease, n (%) | ||||
| Surveillance only | 112 (74.2) | 75 (71.4) | 37 (80.4) | |
| Hypomethylating agent | 6 (4) | 4 (3.8) | 2 (4.4) | |
| Supportive care (G-CSF, ESA, TPO, and transfusions) | 23 (15.2) | 17 (16.2) | 6 (13) | |
| Immunosuppressive agent | 6 (4) | 6 (5.7) | 0 (0) | |
| Bone marrow transplantation | 0 (0) | 0 (0) | 0 (0) | .544 |
| Vitamin C clinical trial | 4 (2.7) | 3 (2.9) | 1 (2.2) | |
| Progression to MN, n (%) | 28 (17.9) | 16 (15.2) | 12 (26.1) | .171 |
| CMML | 6 (4) | 4 (3.8) | 2 (4.3) | |
| MDS | 15 (9.9) | 8 (7.6) | 7 (15.2) | |
| AML | 6 (4) | 3 (2.9) | 3 (6.5) | |
| BPDCN | 1 (0.6) | 1 (1) | 0 (0) | .491 |
| Follow-up (y), median (range) | 2.2 (0.05-12.6) | 2.5 (0.05-12.6) | 1.5 (0.1-5.9) | .002 |
| Total deaths, n (%) | 44 (29.1) | 26 (24.8) | 18 (39.1) | |
| Malignancy related | 14 (31.8) | 6 (23.1) | 8 (44.4) | |
| Cardiac related | 8 (18.2) | 4 (15.4) | 4 (22.2) | .299 |
| Infection related | 10 (22.7) | 8 (30.1) | 2 (11.1) | |
| Other/multifactorial | 12 (27.3) | 8 (30.1) | 4 (22.2) | |
| CHRS score, median (range) | 12 (8.5-15.5) | 12 (8.5-15.5) | 12 (8.5-15.5) | .574 |
| CHRS risk group, n (%) | ||||
| Low | 16 (10.6) | 9 (8.6) | 7 (15.2) | |
| Intermediate | 70 (46.4) | 50 (47.6) | 20 (43.5) | |
| High | 65 (43.1) | 46 (43.8) | 19 (41.3) | .478 |
Variables in bold indicate P < 0.05. AMC, absolute monocyte count; AML, acute myeloid leukemia; ANC, absolute neutrophil count; BPDCN, blastic plasmacytoid dendritic cell neoplasm; CMML, chronic myelomonocytic leukemia; CV, coefficient of variation; ESA, erythropoietin stimulating agents; G-CSF, granulocyte-colony stimulating factor; MCV, mean corpuscular volume; TPO, thrombopoietin receptor agonists; WBC, white blood cell count.
One patient with blasts of 5% had received G-CSF treatment before bone marrow biopsy.